What adverse reactions have been reported with Argatroban?
Argatroban is generally well tolerated in HIT patients, a patient population that often has poor medical status. Major bleeding, minor bleeding, and most frequently observed (2%) nonhemorrhagic adverse events among Argatroban-treated patients in the pivotal trials, ARG-911 and ARG-915, are presented here. The adverse events include all events regardless of relationship to treatment.
